HAYA Therapeutics, SA, a biotechnology company pioneering precision RNA-guided regulatory genome targeting therapeutics that reprogram disease-driving cell states for rare, common, chronic and ...

US telehealth group explores selling ‘compounded medications’ in new markets after buying London-based rival Zava ...

American teens are increasingly turning to the weight-loss drug Wegovy as more families and their doctors gain confidence in ...

EVERYONE’S talking about fat jabs – the ‘miracle’ injections trimming inches off waistlines, and helping turn the tide on the ...

Mazdutide, used in the treatment of obesity and metabolic diseases, could become the first domestically-developed dual-target ...

Regeneron said on Monday its experimental drug helped patients preserve up to 51% of lean mass and lose more fat when used in ...

Regeneron’s shares have declined nearly 17% following the failure of the company’s Dupixent follow-up itepekimab.

The obesity treatment market is booming, with groundbreaking drugs like Eli Lilly's (NYSE: LLY) Zepbound delivering ...

Biocon is gearing up to become a dominant player in the diabetes and obesity drug market. This comes as the pharma world ...

Vertex and Eli Lilly are revolutionizing non-opioid pain management with NaV1.8 advancements. See why I'm bullish about LLY ...

Novo Nordisk was Europe's most valuable company, with a big lead on obesity drugs with its runaway hits Ozempic and Wegovy.

With IRS tax refunds set to arrive, averaging around $3,000, many Americans are weighing the best ways to use the extra cash.